Villanueva Gabriela, de Jong Jill L O, McNeer Jennifer L
Pediatr Ann. 2017 Jan 1;46(1):e13-e18. doi: 10.3928/19382359-20161213-01.
Intravenous immunoglobulin (IVIG) is pooled immunoglobulin G derived from human blood donors. It was introduced in the early 1980s to treat immunodeficiency disorders. Since then, its use has expanded to other fields such as neurology, rheumatology, and hematology. IVIG has been used to provide passive immunity in qualitative and quantitative immunoglobulin disorders, to neutralize antibodies in immune-mediated diseases, and as an immune modulatory agent. The difficulty of producing IVIG in high quantities, in addition to a growing list of "off-label" indications, has resulted in a worldwide shortage and increase in cost. From a pediatric hematology perspective, IVIG is considered an appropriate therapeutic option in autoimmune cytopenias, sometimes coadministrated with steroids. Its use in other hematologic disorders is questionable, and there is not sufficient evidence to recommend it. This article provides clear information to the general pediatrician about indications for IVIG therapy in children with hematologic disorders. [Pediatr Ann. 2017;46(1):e13-e18.].
静脉注射免疫球蛋白（IVIG）是从人类献血者血液中提取的混合免疫球蛋白G。它于20世纪80年代初被引入用于治疗免疫缺陷疾病。从那时起，其用途已扩展到其他领域，如神经病学、风湿病学和血液学。IVIG已被用于在定性和定量免疫球蛋白疾病中提供被动免疫，在免疫介导的疾病中中和抗体，以及作为一种免疫调节剂。除了越来越多的“超说明书”适应症外，大量生产IVIG的困难导致了全球范围内的短缺和成本增加。从儿科血液学的角度来看，IVIG被认为是自身免疫性血细胞减少症的一种合适治疗选择，有时与类固醇联合使用。它在其他血液系统疾病中的应用存在疑问，并且没有足够的证据推荐使用。本文为普通儿科医生提供了关于血液系统疾病患儿IVIG治疗适应症的明确信息。[《儿科年鉴》。2017年；46(1):e13 - e18。]
